Phase 1 safety and tolerability study of BMP-7 in symptomatic knee osteoarthritis

David J Hunter, Marilyn C Pike, Beth L Jonas, Eugene Kissin, Julie Krop, Tim McAlindon, David J Hunter, Marilyn C Pike, Beth L Jonas, Eugene Kissin, Julie Krop, Tim McAlindon

Abstract

Background: There are no proven therapies that modify the structural changes associated with osteoarthritis (OA). Preclinical data suggests that intra-articular recombinant human BMP-7 (bone morphogenetic protein-7) has reparative effects on cartilage, as well as on symptoms of joint pain. The objective of this study was to determine the safety and tolerability as well as dose-limiting toxicity and maximal tolerated dose of intra-articular BMP-7. The secondary objectives were to determine the effect on symptomatic responses through 24 weeks.

Methods: This was a Phase 1, double-blind, randomized, multi-center, placebo-controlled, single-dose escalation safety study consisting of 4 dosing cohorts in participants with knee OA. Each cohort was to consist of 8 treated participants, with treatment allocation in a 3:1 active (intra-articular BMP-7) to placebo ratio. Eligible participants were persons with symptomatic radiographic knee OA over the age of 40. The primary objective of this study was to determine the safety and tolerability of BMP-7 including laboratory assessments, immunogenicity data and radiographic assessments. Secondary objectives were to determine the proportion of participants with a 20%, 50%, and 70% improvement in the WOMAC pain and function subscales at 4, 8, 12, and 24 weeks. Other secondary outcomes included the change from baseline to 4, 8, 12, and 24 weeks for the OARSI responder criteria.

Results: The mean age of participants was 60 years and 73% were female. All 33 participants who were enrolled completed the study and most adverse events were mild or moderate and were similar in placebo and BMP-7 groups. The 1 mg BMP-7 group showed a higher frequency of injection site pain and there was no ectopic bone formation seen on plain x-rays. By week 12, most participants in both the BMP-7 and placebo groups experienced a 20% improvement in pain and overall the BMP-7 group was similar to placebo with regard to this measurement. In the participants who received 0.1 mg and 0.3 mg BMP-7, there was a trend toward greater symptomatic improvement than placebo. The other secondary endpoints showed similar trends including the OARSI responder criteria for which the BMP-7 groups had more responders than placebo.

Conclusions: There was no dose limiting toxicity identified in this study. The suggestion of a symptom response, together with the lack of dose limiting toxicity provide further support for the continued development of this product for the treatment of osteoarthritis.

Trial registration: ClinicalTrials.gov NCT00456157.

References

    1. Prevalence and impact of chronic joint symptoms--seven states, 1996. MMWR - Morbidity & Mortality Weekly Report. 1998;47:345–351.
    1. Dunlop DD, Manheim LM, Song J, Chang RW. Arthritis prevalence and activity limitations in older adults. Arthritis & Rheumatism. 2001;44:212–221.
    1. Prevalence of disabilities and associated health conditions among adults--United States, 1999. [erratum appears in MMWR Morb Mortal Wkly Rep 2001 Mar 2;50(8):149.] MMWR - Morbidity & Mortality Weekly Report. 2001;50:120–125.
    1. Guccione AA, Felson DT, Anderson JJ, Anthony JM, Zhang Y, Wilson PW. et al.The effects of specific medical conditions on the functional limitations of elders in the Framingham Study. American Journal of Public Health. 1994;84:351–358. doi: 10.2105/AJPH.84.3.351.
    1. Glazier RH, Dalby DM, Badley EM, Hawker GA, Bell MJ, Buchbinder R. et al.Management of common musculoskeletal problems: a survey of Ontario primary care physicians.[see comment] CMAJ Canadian Medical Association Journal. 1998;158:1037–1040.
    1. Chevalier X, Mugnier B, Bouvenot G, Chevalier X, Mugnier B, Bouvenot G. [Targeted anti-cytokine therapies for osteoarthritis]. [Review] [26 refs] [French] Bulletin de l Academie Nationale de Medecine. 2006;190:1411–1420.
    1. Furuzawa-Carballeda J, Munoz-Chable OA, Macias-Hernandez SI, Agualimpia-Janning A. Effect of polymerized-type I collagen in knee osteoarthritis. II. In vivo study. Eur J Clin Invest. 2009;39:598–606. doi: 10.1111/j.1365-2362.2009.02144.x.
    1. Furuzawa-Carballeda J, Munoz-Chable OA, Barrios-Payan J, Hernandez-Pando R. Effect of polymerized-type I collagen in knee osteoarthritis. I. In vitro study. Eur J Clin Invest. 2009;39:591–597. doi: 10.1111/j.1365-2362.2009.02154.x.
    1. Griffith DL, Keck PC, Sampath TK, Rueger DC, Carlson WD. Three-dimensional structure of recombinant human osteogenic protein 1: structural paradigm for the transforming growth factor beta superfamily. Proc Natl Acad Sci USA. 1996;93:878–883. doi: 10.1073/pnas.93.2.878.
    1. Massague J, Attisano L, Wrana JL. The TGF-beta family and its composite receptors. Trends Cell Biol. 1994;4:172–178. doi: 10.1016/0962-8924(94)90202-X.
    1. Sieber C, Kopf J, Hiepen C, Knaus P. Recent advances in BMP receptor signaling. Cytokine Growth Factor Rev. 2009;20:343–355. doi: 10.1016/j.cytogfr.2009.10.007.
    1. Wozney JM. Overview of bone morphogenetic proteins. Spine (Phila Pa 1976 ) 2002;27:S2–S8.
    1. Cook SD, Rueger DC. Osteogenic protein-1: biology and applications. Clin Orthop Relat Res. 1996. pp. 29–38.
    1. Merrihew C, Kumar B, Heretis K, Rueger DC, Kuettner KE, Chubinskaya S. Alterations in endogenous osteogenic protein-1 with degeneration of human articular cartilage. J Orthop Res. 2003;21:899–907. doi: 10.1016/S0736-0266(03)00055-X.
    1. Nishida Y, Knudson CB, Knudson W. Osteogenic Protein-1 inhibits matrix depletion in a hyaluronan hexasaccharide-induced model of osteoarthritis. Osteoarthritis Cartilage. 2004;12:374–382. doi: 10.1016/j.joca.2004.01.008.
    1. Jelic M, Pecina M, Haspl M, Kos J, Taylor K, Maticic D. et al.Regeneration of articular cartilage chondral defects by osteogenic protein-1 (bone morphogenetic protein-7) in sheep. Growth Factors. 2001;19:101–113. doi: 10.3109/08977190109001079.
    1. Cook SD, Patron LP, Salkeld SL, Rueger DC. Repair of articular cartilage defects with osteogenic protein-1 (BMP-7) in dogs. J Bone Joint Surg Am. 2003;85-A(Suppl 3):116–123.
    1. Sellers RS, Peluso D, Morris EA. The effect of recombinant human bone morphogenetic protein-2 (rhBMP-2) on the healing of full-thickness defects of articular cartilage. J Bone Joint Surg Am. 1997;79:1452–1463.
    1. Bellamy N, Buchanan WW, Goldsmith CH, Campbell J, Stitt LW. Validation study of WOMAC: a health status instrument for measuring clinically important patient relevant outcomes to antirheumatic drug therapy in patients with osteoarthritis of the hip or knee. Journal of Rheumatology. 1988;15:1833–1840.
    1. Roos EM, Roos HP, Lohmander LS, Ekdahl C, Beynnon BD. Knee Injury and Osteoarthritis Outcome Score (KOOS)--development of a self-administered outcome measure. Journal of Orthopaedic & Sports Physical Therapy. 1998;28:88–96.
    1. Ware JEJ, Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Medical Care. 1992;30:473–483. doi: 10.1097/00005650-199206000-00002.
    1. Pham T, van der HD, Altman RD, Anderson JJ, Bellamy N, Hochberg M. et al.OMERACT-OARSI initiative: Osteoarthritis Research Society International set of responder criteria for osteoarthritis clinical trials revisited. Osteoarthritis & Cartilage. 2004;12:389–399.

Source: PubMed

Sponsors et collaborateurs

Les conditions médicales

Interventions en matière de drogue

3
S'abonner